



## Indrayani Biotech Limited

1133/5 F C Road, Opp. Police Grounds  
Pune 411 016  
Tel/Fax: +91 20 25662021  
Email: info@indrayani.com  
www.indrayani.com  
CIN: L24231PN1992PLC065801

May 29, 2018

To,  
Bombay Stock Exchange Ltd.  
Department of Corporate Services,  
25<sup>th</sup> Floor, P.J. Towers, Dalal Street,  
Mumbai - 400 001.

Dear Sir,

**Ref.: Scrip code '526445'**

**Re.: Audited Financial Results for the quarter and year ended March 31, 2018.**

The Board of Directors, in their meeting duly held on 29<sup>th</sup> May, 2018 has approved the Audited Financial Results for the quarter and year ended on March 31, 2018.

Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose the followings:

- 1) Statement of the Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2018.
- 2) The Report of Auditors is with unmodified opinion with respect to the Financial Results of the Company for the Quarter and Year ended 31<sup>st</sup> March, 2018.


The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 12:30 p.m.

Please take on your records.

Thank you,

Yours sincerely,  
For Indrayani Biotech Ltd.

  
Prakash Bang  
Managing Director  
DIN: 00088837



Encl.: As above.

**INDRAYANI BIOTECH LIMITED**


Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.

Telefax: 020 - 25662021, Web: www.indrayani.com, Email: info@indrayani.com, CIN: L24231PN1992PLC065801

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2018**

PARTICULARS	Quarter Ended			Year Ended		Rs. In Lakhs
	31 <sup>st</sup> March, 2018	31 <sup>st</sup> December, 2017	31 <sup>st</sup> March, 2017	31 <sup>st</sup> March, 2018	31 <sup>st</sup> March, 2017	
	Audited	Unaudited	Audited	Audited	Audited	
<b>Income</b>						
I Revenue from Operations	-	-	-	-	-	-
II Other Income	-	-	-	-	-	-
<b>III Total Income</b>	-	-	-	-	-	-
<b>IV Expenses</b>						
Cost of Materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	-	-	-	-	-	-
Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
Employee benefits expenses	1.20	0.90	1.10	3.60	2.70	2.70
Finance Cost	-	-	-	0.02	0.03	0.03
Depreciation and amortisation expense	-	-	-	-	-	-
Other expenses						
1. Audit Fees	0.71	-	0.20	0.71	0.20	0.20
2. Bank and Wire Transfer Charges	-	-	-	-	-	-
3. Legal & Professional Fees	1.96	0.50	0.69	6.89	5.95	5.95
4. Postage, Telephone & Telegram	0.01	-	-	0.01	0.02	0.02
5. Travelling & Conveyance	0.05	-	0.02	0.05	0.02	0.02
6. Filing Fees & Subscriptions	0.07	0.03	0.15	0.39	0.51	0.51
7. Advertisement & Sales Promotion	0.24	0.13	0.17	0.71	0.75	0.75
8. Interest and Finance Charges	-	-	-	-	0.08	0.08
9. Prior Period Expenses	-	-	-	-	-	-
10. Printing & Stationary	-	-	-	-	0.11	0.11
11. Rates & Taxes	-	-	-	0.03	0.03	0.03
<b>Total Other Expenses</b>	3.04	0.66	1.23	8.78	7.66	7.66
<b>Total Expenses (IV)</b>	<b>4.24</b>	<b>1.56</b>	<b>2.33</b>	<b>12.40</b>	<b>10.39</b>	<b>10.39</b>
<b>Profit / (Loss) before exceptional and tax (I-IV)</b>	<b>(4.24)</b>	<b>(1.56)</b>	<b>(2.33)</b>	<b>(12.40)</b>	<b>(10.39)</b>	<b>(10.39)</b>
VI Exceptional Items						

INDRAYANI BIOTECH LTD.



*[Signature]*  
MANAGING DIRECTOR

VII	Profit / (Loss) before tax (V-VI)	(4.24)	(1.56)	(2.33)	(12.40)	(10.39)
VIII	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(4.24)	(1.56)	(2.33)	(12.40)	(10.39)
X	Profit / (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Net Profit / (Loss) from Discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	(4.24)	(1.56)	(2.33)	(12.40)	(10.39)
XIV	Other Comprehensive Income (OCI)					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period).	(4.24)	(1.56)	(2.33)	(12.40)	(10.39)
	Paid-up equity share capital (Face value of Rs. 10/- each)	364.39	364.39	364.39	364.39	364.39
	Reserves excluding revaluation reserve	-	-	-	(424.52)	(412.12)
XVI	Earnings per share (for continuing operation) :					
	Basic:	(0.12)	(0.04)	(0.06)	(0.34)	(0.29)
	Diluted:	(0.12)	(0.04)	(0.06)	(0.34)	(0.29)
XVII	Earnings per share (for discontinued operation) :					
	Basic:	-	-	-	-	-
	Diluted:	-	-	-	-	-
XVIII	Earnings per share (for discontinued & continuing operation)					
	Basic:	(0.12)	(0.04)	(0.06)	(0.34)	(0.29)
	Diluted:	(0.12)	(0.04)	(0.06)	(0.34)	(0.29)

**Notes:**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 29<sup>th</sup> May, 2018. The Statutory Auditors of the Company have conducted an audit of the above financial results. **INDRAYANI BIOTECH LTD.**




*(Signature)*  
MANAGING DIRECTOR

2. The above financial results for the quarter and for the year ended 31<sup>st</sup> March, 2018 are prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. Beginning 01<sup>st</sup> April 2017, the Company has for the first time adopted Ind AS with a transition date of 01<sup>st</sup> April 2016.
3. The format for financial results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November 2015 has been modified to comply with the requirements of SEBI's circular dated 05<sup>th</sup> July 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013, which are applicable to companies that are required to comply with Ind AS.
4. The Ind AS-compliant corresponding figures in the previous year have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
5. The Company operates in a single business segment - Travel Technology & Support Services. Hence, no segment wise results are given.
6. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Description	Year to date figure for the previous year ended March 31, 2017 (Audited)
Net profit or loss as per previous GAAP (Indian GAAP)	(10.39)
Add/Less: IND AS adjustments:	-
Net profit/loss as per Ind AS	(10.39)
Other comprehensive income, net of income tax	-
<b>Total comprehensive income for the period</b>	<b>(10.39)</b>

7. The fixed asset has been impaired as per IND AS.
8. The figures of the quarter ended 31<sup>st</sup> March, 2018 and 31<sup>st</sup> March, 2017 are the balancing figures between the audited figures in respect of the full financial year and the figures up to the third quarter of the relevant financial year.
9. Pursuant to public announcement dated 02/01/2018 and subsequently open offer made by Mr. Kasiraman Sayee Sundar, the shareholding of the existing promoters would be transfer to him. The erstwhile promoters will be ceases to the promoters and Mr. Kasiraman Sayee Sundar will take over the control and management of the Company.

For Indrayani Biotech Limited



*Prakash Bang*  
Prakash Bang  
Managing Director  
DIN: 00088837

Date: 29<sup>th</sup> May, 2018  
Place: Pune


**STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2018**

(Rs. in Lakhs)

Sr. No.	Standalone Statement of Assets and Liabilities	Current year ended 31/03/2018	Previous year ended 31/03/2017
	<b>Particulars</b>		
	Date of start of reporting period	01/04/2017	01/04/2016
	Date of end of reporting period	31/03/2018	31/03/2017
	Whether result of Audited/Unaudited	Audited	Audited
	Nature of report standalone/consolidated	Standalone	Standalone
<b>A.</b>	<b>ASSETS</b>		
<b>1.</b>	<b>Non-current assets</b>		
a)	Property, plant and equipment	-	-
b)	Capital work in progress	-	-
c)	Investment property	-	-
d)	Goodwill	-	-
e)	Other intangible assets	-	-
f)	Intangible assets under development	-	-
g)	Biological assets other than bearer plants	-	-
h)	Financial assets	-	-
	i) Investments	-	-
	ii) Trade receivables	-	-
	iii) Loans	-	-
	iv) Other non-current financial assets	-	-
i)	Deferred tax assets (net)	-	-
j)	Others non-current assets	-	-
	Sub Total Non - Current Assets	-	-
<b>2.</b>	<b>Current Assets</b>		
a)	Inventories	-	-
b)	Financial Assets	-	-
	i) Investments	-	-
	ii) Trade Receivables	-	-
	iii) Cash & Cash Equivalents	-	-
	iv) Bank Balances other than (iii) above	1.05	0.22
	v) Loans	-	-
	vi) Other financial assets	-	-
c)	Current tax assets (net)	-	-
d)	Other current assets	-	-
	Sub Total - Current Assets	1.05	0.22
	<b>Total Assets</b>	<b>1.05</b>	<b>0.22</b>
<b>B.</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>EQUITY</b>		
a)	Equity share capital	364.39	364.39
b)	Other equity		
	Reserves	(424.52)	(412.12)
	<b>LIABILITIES</b>		
<b>1.</b>	<b>Non-current liabilities</b>		
a)	Financial liabilities		
	i) Borrowings	60.00	47.50
	ii) Trade payables	-	-
	iii) Other financial liabilities	-	-
b)	Provisions	-	-


**INDRAYANI BIOTECH LTD.**

*Abang*  
**MANAGING DIRECTOR**




c)	Deferred tax liabilities (net)	-	-
d)	Other non-current liabilities	-	-
	Sub Total Non - Current Liabilities	60.00	47.50
<b>2.</b>	<b>Current liabilities</b>		
a)	Financial liabilities	-	-
	i) Borrowings	-	-
	ii) Trade payables	0.44	0.22
	iii) Other financial liabilities	-	-
b)	Other current liabilities	-	-
c)	Provisions	0.74	0.23
d)	Current tax liabilities (Net)	-	-
	Sub Total - Current Liabilities	1.18	0.45
	<b>Total Equity and Liabilities</b>	<b>1.05</b>	<b>0.22</b>

For Indrayani Biotech Limited



Prakash Bang  
Managing Director  
DIN: 00088837



Date: 29<sup>th</sup> May, 2018  
Place: Pune

**Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company  
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

To  
The Board of Directors  
Indrayani Biotech Limited

1. We have audited the quarterly financial results of **M/s. Indrayani Biotech Limited** (CIN-L24231PN1992PLC065801) for the quarter ended 31<sup>st</sup> March, 2018 and the year to date results for the period 01/04/2017 to 31/03/2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
  - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
  - (ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31/03/2018 as well as the year to date results for the period from 01/04/2017 to 31/03/2018.

For S S S S & Company  
Chartered Accountants  
FRN : 132839W



Shashikant C Bhandari  
Partner (M. No. 045186)



Place : Pune  
Date : 29/05/2018